Frontiers in Pharmacology | Drugs Outcomes Research and Policies

Systematic Review

Accepted on 08 May 2025

What is the best first-line combination regimen for advanced EGFR-mutated non-small cell lung cancer: a network meta-analysis and systemic review

in Drugs Outcomes Research and Policies

Chuang Yang
Yunfei Wang
Yiyong Sun
Ying Sun
Rongyu Zhang
Chengjun Wang
Yanan Song
Wen Zhao
Jisheng Li

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1572115

130 views

Systematic Review

Published on 02 May 2025

Cost-effectiveness analyses of amivantamab plus lazertinib and lazertinib versus osimertinib in non-small cell lung cancer with EGFR mutations

in Drugs Outcomes Research and Policies

Hui Zhang
Yueyun Li
Yuhang Liu
Haonan Li
Hong Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1527614

1,522 views

Original Research

Published on 01 May 2025

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for patients with unresectable hepatocellular carcinoma: a cost–utility analysis in China and the United States

in Drugs Outcomes Research and Policies

Qiuling Zhao
Yimin He
Zilin Nian
Yongjian Huang
Ruyi Huang
Lijun Lai
Lin Yang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1404389

875 views

Original Research

Published on 01 May 2025

Towards a sustainable rare disease and orphan drug ecosystem in Saudi Arabia: policy insights from a multi-stakeholder workshop

in Drugs Outcomes Research and Policies

Ghada Mohammed Abozaid
Hussain Abdulrahman Al-Omar
Abdulaziz Alrabiah
Asma AlMuaither
Amy Jayne McKnight

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1583477

1,235 views

Brief Research Report

Published on 30 Apr 2025

Regulatory challenges of digital health: the case of mental health applications and personal data in South Africa

in Drugs Outcomes Research and Policies

Marietjie Botes

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1498600

1,373 views

Original Research

Published on 29 Apr 2025

Trajectories of potentially inappropriate medication use among older adults in Saudi Arabia

in Drugs Outcomes Research and Policies

Fouad F. Jabri
Yajun Liang
Kristina Johnell
Jette Möller

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1568160

606 views

Original Research

Published on 28 Apr 2025

A multinational cross-sectional study on knowledge, attitudes, and practices towards magnesium supplements

in Drugs Outcomes Research and Policies

Rana Abutaima
Muna Barakat
Samar Thiab
Hana M. Sawan
Malak Amer
Reem Alzayer
Doaa H. Abdelaziz
Noha O. Mansour
Fatima Saleh
Wael Abu Dayyih

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1550695

1,554 views

Original Research

Published on 28 Apr 2025

Prevalence, risk characteristics, and prediction of low-dose edoxaban treatment in hospitalized patients: a multicenter, observational cohort study

in Drugs Outcomes Research and Policies

Shujuan Zhao
Hengfen Dai
Jiaxin Chen
Ming Ni
Wenxing Peng
Xiaoyu Li
Fen Li
Boya Chen
Haixia Cai
Yinping Liu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1427634

1,151 views

Original Research

Published on 25 Apr 2025

Characteristics, clinical evidence and implementation effects of conditional approvals for drugs in China, a pooled analysis from 2020 to 2023

in Drugs Outcomes Research and Policies

Li Yang
Shuoxin Fan
Jie Zhang
Geyun Huang
Yaoyang Tang
Lijia Xue

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1501525

824 views

Original Research

Published on 24 Apr 2025

Effective inhaler technique education is achievable - assessment and comparison of five inhaler devices errors

in Drugs Outcomes Research and Policies

Monika Marko
Magdalena Klimczak
Marharyta Sobczak
Maciej Wojakiewicz
Tomasz Dębowski
Andrzej Emeryk
Rafał Pawliczak

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1538283

1,114 views

Policy and Practice Reviews

Published on 17 Apr 2025

Different routes the same destination: a comparative study of antitrust regulation for pharmaceutical industry in the United States and China

in Drugs Outcomes Research and Policies

Jie Weng
Nailiang Liu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1557876

980 views

Original Research

Published on 15 Apr 2025

Statins and long-term risk of revision surgery after total hip arthroplasty in osteoarthritis: a multi-source data linkage study

in Drugs Outcomes Research and Policies

Andrea D'Amuri
Barbara Bordini
Mauro Pagani
Jacopo Ciaffi
Claudio D'Agostino
Alberto Di Martino
Cesare Faldini
Francesco Ursini

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1492200

787 views

Original Research

Published on 14 Apr 2025

Off-label drug use in China after the Physician Law (2021): legal challenges and solutions

in Drugs Outcomes Research and Policies

Shenbao Liang
Fanxian Cai

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1547418

790 views

Original Research

Published on 14 Apr 2025

Optimization and impact of an evidence-based pre-audit prescription decision system in primary healthcare settings

in Drugs Outcomes Research and Policies

Xiao-Hui Yue
Lei Yang
Jing-Jing Zhong
Hong-Mei Liu
Dan Wang
Xue Tao
Gao-Feng Zheng

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1491810

912 views

Original Research

Published on 11 Apr 2025

From clinical trials to informing clinical decision-making: a review of patient-reported outcomes in nononcology medicines approved by the European Medicines Agency (2018–2022)

in Drugs Outcomes Research and Policies

Sarah Sauchelli
Courtney Levy
Ari Gnanasakthy
Vaidehi Dave
Lynda Doward
Kristina A. Fitzgerald
Robyn Carson

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1536401

1,829 views

Clinical Trial

Published on 11 Apr 2025

Efficacy and safety of intermittent intravenous doxercalciferol in the treatment of secondary hyperparathyroidism in Chinese patients on maintenance hemodialysis: a phase II, open-label, prospective, multicenter study

in Drugs Outcomes Research and Policies

Guang Yang
Yaoyu Huang
Yifei Ge
Xiangbao Yu
Li Liu
Li Xiang
Bin Liu
Chaoqing Gao
Changhua Liu
Yong Xu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1574679

816 views